

## **ANNEXIN PRESENTS AT REDEYE'S FIGHT CANCER EVENT ON JANUARY 24**

**Annexin Pharmaceuticals today announces that the company is participating at Redeye's theme event Fight Cancer on January 24, 2024. CEO Anders Haegerstrand will present the latest development in the company's cancer initiative with the drug candidate ANXV.**

The presentation and moderated Q&A session will be held in English and is broadcasted live via Redeye's website <https://www.redeye.se/events/966280/redeye-theme-fight-cancer-2?tab=schedule>

The presentation will also be available at Annexin's website afterwards at <https://annexinpharma.se/investerare/presentationer/>

Time: January 2024 at 15:56 CET

Place: Redeye, Mäster Samuelsgatan 42, Stockholm

**For further information, please contact:**

Anders Haegerstrand, CEO

Phone: +46 (0)70 575 50 37

Mail: [anders.haegerstrand@annexinpharma.com](mailto:anders.haegerstrand@annexinpharma.com)

**About Annexin Pharmaceuticals AB**

Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5. The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company's Certified Adviser.

**Attachments**

[Annexin presents at Redeye's Fight Cancer event on January 24](#)